The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer1
- 1 March 1998
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 19 (3) , 167-177
- https://doi.org/10.1016/s0169-5002(97)00086-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Positron Emission Tomography in the Pretreatment Evaluation and Follow-Up of Non-Small Cell Lung Cancer Patients Treated with Radiotherapy: Preliminary FindingsAmerican Journal of Clinical Oncology, 1996
- 60 Multimodality nuclear medicine imaging in radiation treatment planning for lung cancer: Challenges and prospectsInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Mediastinal staging of non-small-cell lung cancer with positron emission tomography.American Journal of Respiratory and Critical Care Medicine, 1995
- PET-FDG Imaging and Transthoracic Needle Lung Aspiration Biopsy in Evaluation of Pulmonary LesionsChest, 1995
- Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET)The Journal of Thoracic and Cardiovascular Surgery, 1995
- Characterization of Chest Masses by FDG Positron Emission TomographyClinical Nuclear Medicine, 1995
- Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.Radiology, 1995
- Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.Radiology, 1992
- Integration of multimodality imaging data for radiotherapy treatment planningInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Glucose utilizationin vivo by human pulmonary neoplasmsCancer, 1987